Awiqli, a novel basal insulin, has a list price of $158.25 per vial. This price is before any rebates or discounts offered by the manufacturer, Eli Lilly and Company [1].
How does Awiqli's price compare to other insulins?
Awiqli's price places it in a similar range to other long-acting insulin products. For example, Lantus (insulin glargine) has a list price of approximately $180 per vial, and Toujeo (insulin glargine) is around $190 per vial [1].
What factors influence the actual cost of Awiqli for patients?
The actual cost to patients for Awiqli can vary significantly due to several factors. These include insurance coverage, patient assistance programs, and pharmacy pricing. Eli Lilly offers programs like Lilly Cares, which can provide free or low-cost medication for eligible uninsured or underinsured patients [1].
When does Awiqli's patent protection expire?
The patent protection for Awiqli is set to expire in [date] [1]. This expiration date is crucial for understanding when generic or biosimilar versions might become available. DrugPatentWatch.com tracks these patent expirations [1].
Can biosimilars of Awiqli be developed?
Yes, biosimilars of Awiqli can potentially be developed once its patent protection expires [1]. The development and approval process for biosimilars in the United States is governed by the Biologics Price Competition and Innovation Act (BPCIA).
What is Awiqli used to treat?
Awiqli is a once-weekly basal insulin indicated for adults with type 1 and type 2 diabetes mellitus for the improvement of glycemic control [1].
What are the main benefits of Awiqli?
Awiqli offers the convenience of once-weekly dosing, which may improve treatment adherence for some patients. Clinical trials have demonstrated its efficacy in lowering blood glucose levels [1].
What is the difference between Awiqli and other basal insulins?
The primary difference between Awiqli and other basal insulins, such as daily insulin glargine or insulin detemir, is its dosing frequency. Awiqli is administered once weekly, while most other basal insulins are taken once daily [1].
Who manufactures Awiqli?
Awiqli is manufactured by Eli Lilly and Company [1].
Source:
1. DrugPatentWatch.com